Study wrapper · #1211
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.
Editor's note
Post hoc analyses always call for some caution, but this one draws on four large randomized trials and the gap is not subtle: triple-endpoint achievement of 22-38% on tirzepatide against 1-8% on placebo, significant across every threshold. Composite endpoints like this are increasingly how the field frames cardiometabolic benefit beyond the number on the scale. The dedicated cardiovascular outcome trials for tirzepatide are still running, and those remain the real test of whether these biomarker shifts translate into fewer events.
Plain-language abstract
Looking back across the four SURMOUNT trials, researchers asked how many participants hit three targets at once: losing at least 5% of body weight, lowering systolic blood pressure by at least 5 mmHg, and getting non-HDL cholesterol under 130 mg/dL. Roughly a third of people on tirzepatide reached all three, compared with 8% or fewer on placebo — and about a quarter still did so even when the bar was raised to 15% weight loss.